With a lower price tag and fewer complications than sedated endoscopy, experts said the transnasal approach could help primary care physicians catch potential GI cancers early.
The indication is for use in adult patients with previously treated intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.